No products in the cart
Topical Tripeptide-29 as a Synthetic Equivalent to Collagen
The synthetic equivalent of one of collagens constituent units is tripeptide-29. Tripeptide-29 serves as a building block for large collagen molecules. As a result, it can change the amino acid sequence and relative frequency of a collagen molecule, including its superstructure, tertiary, and quaternary properties. It is important to remember that collagen is vital to wound healing and tissue control.
According to research, tripeptide-29 can have a wide range of physiological effects.
According to in vitro research, Tripeptide-29 is a limited antagonist of collagen receptor-GPVI. Platelet surfaces are packed with GPVI, the protein responsible for the early production of blood clots. Collagen fibers are referred to as thrombogenic in this context because they play a significant part in the collagen-mediated stimulation of the collection of collagen in vascular tissues, which is the first stage in tissue repair and clot formation.
Tripeptide-29 boosts GPVI activation, suggesting it could be useful in discovering how to create a perfect clotting environment in cases of bleeding and clotting abnormalities.
The Roles of Tripeptide-29 (Topical)
Collagen is one of the most common compounds found in animals. All animals, reptiles, humans, fish, birds, and even algae contain it. It plays a role in muscle fibers, skin, ligament and tendon structures, bone, teeth, scar formation, cartilage, cell signaling, transmembrane proteins like integrin and fibronectin, placental structure, and the vitreous humor of the eye.
- The Regulation of Tissue Fibrosis: Tripeptide-29 suppresses the activity of dipeptidyl peptidase-IV in vitro, utilizing fish scales, bovine skin, pig skin, and chicken feet (DPP4). DPP4 is a cell apoptosis enzyme identified in immunological signaling cells. Growth factors, neuropeptides, chemokines, and vasoactive peptides are all hampered by it since it is an inherent element of cell membranes. Its duties are not restricted since it is involved in glucose metabolism, which breaks down incretins—a hormone that aids in lowering blood glucose.
DPP4 studies in animal models show that it fosters fibrotic growth in organs such as the liver and kidney. Tripeptide-29 can increase cellular glucose absorption and minimize renal fibrosis while also inhibiting DPP4 activity. As a result, various research pathways have opened up, not only for treating diabetes but also as pathologic sequelae.
- The effect of Tripeptide-29 on Collagen Stability: Tripeptide-29, according to studies, may be effective in modulating collagen stability. It has also allowed scientists to realize that the final peptide in the tripeptide monomer modulates the collagen structure (in an A-B-C trend, C has the most influential capacity on collagen stability).
- The Effect of Tripeptide-29 on Skin Tone: The significance of tripeptide-29 in protecting the skin against the aging process has been the subject of recent studies. The research on Tripeptide-29 reveals promising results in reducing aging by improving contour, reducing skin deformation, and improving moisture. It enhances skin tone by smoothing skin texture and preventing brown and red patches from appearing. In 90 percent of the animal research, Tripeptide-29 resulted in better moisturization while increasing flexibility.
Topical tripeptide-29 synergy with certain hexapeptides improves skin turnover and reduces fine wrinkles, eye hollowing, eye bags, and crow’s feet.
- Tripeptide-29 is an effective Radical Scavenger: Damage caused by free radicals is the fundamental cause of tissue and cellular aging. Though the body has various protections to counteract the consequences of free radical damage, these barriers grow less effective with time. According to studies, Tripeptide-29 hydrolysate is a potent radical scavenger.
Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.
Dr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson & Johnson and Sanofi.